FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL							
OMB Number:	3235-0104						
Estimated average burden							
hours per response:	0.5						

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* DiBiase Mary.				of Event Requirent (Month/Day/ 2021		3. Issuer Name and Ticker or Trading Symbol X4 Pharmaceuticals, Inc [XFOR]						
(Last) (First) (Middle) C/O X4 PHARMACEUTICALS INC.				Relationship of Reporting Person(s) to (Check all applicable) Director			ssuer 10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)			
61 NORTH BEACON STREET 4TH FLOOR			_			X Officer (give title below)	Other (specify below)		Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person			
(Street) BOSTON MA 02134					Chief Operating Of	ficer		Form filed by More than One Reporting Person				
(City)	(State)	(Zip)										
Table I - Non-Derivative Securities Beneficially Owned												
1. Title of Security (Instr. 4)					Owned (Instr. 4)	3. Ownership Fo Direct (D) or Ind (Instr. 5)		lature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock						64,475(1)	D					
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)												
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		Security (Instr. 4)		4. Conversion or Exercise	or Indirect (I)	6. Nature of Indirect Beneficial Ownership (Instr. 5)			
				Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	(Instr. 5)			
Stock Option (right to buy)				(2)	07/11/2027	Common Stock	15,205	6.84	D			
Stock Option (right to buy)			(3)	04/10/2028	Common Stock	1,900	7.08	D				
Stock Option (right to buy)			(4)	08/21/2028	Common Stock	10,112	10.44	D				
Stock Option (right to buy)				(5)	06/16/2029	Common Stock	9,469	14.75	D			
Stock Option (right to buy)				(6)	02/09/2030	Common Stock	22,500	10	D			
Stock Option (right to buy)				(7)	06/09/2030	Common Stock	7,500	8.69	D			

Explanation of Responses:

- 1. Includes 58,293 shares underlying restricted stock units issued to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer and has no expiration date. Of the total shares underlying outstanding restricted stock units, (a) 2,916 shares will vest on June 15, 2022; (a)217 shares will vest on June 23, 2022; (5,834 shares will vest on August 17, 2022; (2,916 shares will vest on June 15, 2023 and (2,917 shares will uses on June 23, 2022 shares will vest on June 23, 2022 shares will vest on June 24, 2022 and (2,917 shares will vest on June 24, 2023 and (2,917 shares will vest on June 25, 2023 and (2,917 shares will ves
- $2.\ Fully$ vested as of July 12, 2021.
- 3. Fully vested as of April 11, 2020
- 4. Twenty five percent (25%) of the shares underlying the option vested on August 22, 2019 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.
- 5. Twenty five percent (25%) of the shares underlying the option vested on June 17, 2020 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.
- 6. Twenty five percent (25%) of the shares underlying the option vested on February 10, 2021 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.

 7. Twenty five percent (25%) of the shares underlying the option vested on June 10, 2021 and one thirty sixth (1/36th) of the shares underlying the award vest monthly thereafter subject to the reporting person providing continuous services to the Issuer on such dates.

Remarks:

/s/ Derek M. Meisner, attorney-in-fact 09/10/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints each of Daniel I. Goldberg, Courtney T. Thorne, Brigitte Eich

- (1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC
- (2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Fo association or any similar authority; and
- (3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of bend The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below. Date: _/s/ Mary DiBiase_____

Mary DiBiase